Jan A. Burger
Leukaemia specialist who was lead author of RESONATE-2, the trial that made ibrutinib a first-line treatment for chronic lymphocytic leukaemia in older patients.
Overview
Jan Burger is a haematologist and laboratory investigator at MD Anderson Cancer Center. He was first author of the 2015 New England Journal of Medicine report of RESONATE-2, which showed that ibrutinib improved progression-free and overall survival compared with chlorambucil in previously untreated older patients with CLL, establishing BTK inhibition as first-line therapy. His laboratory studies how the tissue microenvironment supports CLL cells.
Similar pages
not linked directly; found by shared links- PersonEric Jonasch
Shares MD Anderson Cancer Center and the tags targeted-therapy, trialist.
- PersonFrancesco Lo-Coco
Shares the tags leukaemia, trialist.
- PersonHervé Dombret
Shares the tags leukaemia, trialist.
- PersonJeffrey E. Lancet
Shares the tags leukaemia, trialist.
- TrialA Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period
Shares Chronic lymphocytic leukaemia, first treatment, Chronic lymphocytic leukaemia.
- PersonAleksandar Sekulic
Shares the tags targeted-therapy, trialist.
- PersonAlice T. Shaw
Shares the tags targeted-therapy, trialist.
- PersonAndrea Sartore-Bianchi
Shares the tags targeted-therapy, trialist.